147 results
8-K
EX-99.1
TLPH
Talphera Inc.
6 Mar 24
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
research and development costs.
The divestment of DSUVIA represents a discontinued operation; accordingly, all historical operating results … and expenses:
Research and development (1)
Selling, general and administrative (1)
Impairment of property and equipment
Total operating costs
8-K
EX-99.1
TLPH
Talphera Inc.
22 Jan 24
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
5:12pm
approximately $9.4 million. Cash operating expenses, or selling, general and administrative, and research and development expenses, excluding stock-based
8-K
EX-99.1
xsno 8nl75ek
8 Nov 23
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
nki4sg71 iknpch
10 Aug 23
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.2
hefqevhs9jz0j6l
31 Jul 23
Other Events
9:47pm
8-K
EX-99.1
0iyxt4qo7rv8lis7ax4
31 Jul 23
Other Events
9:47pm
8-K
EX-99.1
ycn1bs
10 May 23
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.2
0av 0fzxm
7 Apr 23
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
3:37pm
8-K
EX-99.1
02lribrk7ywxqu3ohs3
30 Mar 23
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
424B5
lkodgrkj8wx5rjwt
28 Dec 22
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
knh6q8jr
14 Nov 22
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:10pm